ScholarLens Back to search
2021•ERJ Open ResearchOpen access

Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma

Katrine Prætorius, Daniel Pilsgaard Henriksen, Johannes Martin Schmid, Pernille Printzlau, Lars Pedersen, Hanne Madsen, Ehm A. Andersson, Louise Klokker, Bo Chawes

Open full text 11 citations

Abstract

This indirect comparison of dupilumab, mepolizumab and omalizumab for patients with severe type 2 asthma fulfilling start-up criteria for more than one drug shows no significant efficacy differenceshttps://bit.ly/3pK9Nf9

Open-access reader

About this research paper

What this paper is about

This indirect comparison of dupilumab, mepolizumab and omalizumab for patients with severe type 2 asthma fulfilling start-up criteria for more than one drug shows no significant efficacy differenceshttps://bit.ly/3pK9Nf9

Why it matters

OpenAlex reports 11 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

This indirect comparison of dupilumab, mepolizumab and omalizumab for patients with severe type 2 asthma fulfilling start-up criteria for more than one drug shows no significant efficacy differenceshttps://bit.ly/3pK9Nf9

Key concepts: Dupilumab, Mepolizumab, Omalizumab, Medicine, Asthma, Dermatology, Internal medicine, Immunology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma — Research Paper | ScholarLens